2010
Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients
Agarwal S, Loh YH, McLoughlin EM, Huang J, Park IH, Miller JD, Huo H, Okuka M, dos Reis RM, Loewer S, Ng HH, Keefe DL, Goldman FD, Klingelhutz AJ, Liu L, Daley GQ. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 2010, 464: 292-296. PMID: 20164838, PMCID: PMC3058620, DOI: 10.1038/nature08792.Peer-Reviewed Original ResearchConceptsDyskeratosis congenita cellsDyskeratosis congenita patientsPluripotency-associated transcription factorsInduced pluripotent stem cellsPluripotent stem cellsTelomerase componentsTranscription factorsIPS cell technologyGenetic lesionsMultiple tissuesStem cellsDyskeratosis congenitaTERC expressionCellsElongationTelomeraseMaintenanceExpressionCell technology
2009
Telomere Elongation in Dyskeratosis Congenita Induced Pluripotent Stem Cells.
Agarwal S, Loh Y, McLoughlin E, Huang J, Park I, Miller J, Huo H, Okuka M, dos Reis R, Loewer S, Keefe D, Goldman F, Klingelhutz A, Liu L, Daley G. Telomere Elongation in Dyskeratosis Congenita Induced Pluripotent Stem Cells. Blood 2009, 114: 497. DOI: 10.1182/blood.v114.22.497.497.Peer-Reviewed Original ResearchTelomerase RNA componentAutosomal dominant dyskeratosis congenitaPatient-specific iPS cellsInduced pluripotent stemIPS cellsDominant dyskeratosis congenitaSelf-renewal capacitySomatic cellsTERC locusDyskeratosis congenitaPluripotency-associated transcription factorsPrimary somatic cellsHallmarks of pluripotencyInduced pluripotent stem cellsTelomere lengthHuman iPS cellsHuman degenerative disordersPluripotent stem cellsTranscriptional silencingPluripotent stateTelomerase functionSteady-state levelsTranscription factorsRNA componentIPS lines